Bleeding-related hospital admissions and 30-day readmissions in patients with non-valvular atrial fibrillation treated with dabigatran versus warfarin-Reference-Cited by-同舟云学术

Bleeding-related hospital admissions and 30-day readmissions in patients with non-valvular atrial fibrillation treated with dabigatran versus warfarin

Published:2017-08-17 Issue:10 Volume:15 Page:1923-1933
ISSN:1538-7933
Container-title:Journal of Thrombosis and Haemostasis
language:en
Short-container-title:J Thromb Haemost

Author:

Lau W. C. Y.¹,Li X.¹,Wong I. C. K.¹²,Man K. K. C.¹³,Lip G. Y. H.⁴⁵,Leung W. K.⁶,Siu C. W.⁶,Chan E. W.¹

Affiliation:

1. Centre for Safe Medication Practice and Research; Department of Pharmacology and Pharmacy; Li Ka Shing Faculty of Medicine; The University of Hong Kong; Hong Kong

2. Research Department of Practice and Policy; UCL School of Pharmacy; London UK

3. Department of Pediatrics and Adolescent Medicine; Li Ka Shing Faculty of Medicine; The University of Hong Kong; Hong Kong

4. Institute of Cardiovascular Sciences; University of Birmingham; Birmingham UK

5. Aalborg Thrombosis Research Unit; Department of Clinical Medicine; Aalborg University; Aalborg Denmark

6. Department of Medicine; Li Ka Shing Faculty of Medicine; The University of Hong Kong; Hong Kong

Funder

Hong Kong Research Grants Council, General Research Fund

East-West Center

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jth.13780/fullpdf

Reference66 articles.

1. All-cause and bleeding-related health care costs in warfarin-treated patients with atrial fibrillation;Ghate;J Manag Care Pharm,2011

2. Dabigatran versus warfarin in patients with atrial fibrillation;Connolly;N Engl J Med,2009

3. Novel oral anticoagulant use among patients with atrial fibrillation hospitalized with ischemic stroke or transient ischemic attack;Patel;Circ Cardiovasc Qual Outcomes,2015

4. Fatal gastrointestinal hemorrhage after a single dose of dabigatran;Kernan;Clin Toxicol (Phila),2012

5. Evaluation of dabigatran bleeding adverse reaction reports in the FDA adverse event reporting system during the first year of approval;McConeghy;Pharmacotherapy,2014

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Using machine learning to predict the bleeding risk for patients with cardiac valve replacement treated with warfarin in hospitalized;Pharmacoepidemiology and Drug Safety;2024-02

2. Cardiovascular pharmacogenomics – Molecular basis of protective and adverse drug response;Genomic and Molecular Cardiovascular Medicine;2024

3. Oral Anticoagulation in Patients with Chronic Liver Disease;Medicina;2023-02-12

4. Cardiovascular precision medicine – A pharmacogenomic perspective;Cambridge Prisms: Precision Medicine;2023

5. Medication Regimen Complexity and Risk of Bleeding in People Who Initiate Oral Anticoagulants for Atrial Fibrillation: A Population-Based Study;The Journals of Gerontology: Series A;2022-09-27